3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
14
Leukemia, Myeloid, Acute
8
Triple Negative Breast Neoplasms
3
Leukemia
3
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Primary Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
HER2-negative Breast Cancer
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cyclophosphamide
22
blinatumomab
18
Cytarabine
15
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Lenalidomide
7
Dexamethasone
7
Methotrexate
6
Daunorubicin
6
Mercaptopurine
5
daratumumab
4
Whole-Body Irradiation
4
Vincristine
4
Melphalan
4
Idarubicin
4
Etoposide
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Maintenance
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Cladribine
3
Asparaginase
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm, Residual
×
Anthracyclines
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn